Login / Signup

Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data.

Catherine S Y LecatCaroline BesleyRachael E HoughAsim KhwajaCaroline FurnessDavid I MarksAdele K Fielding
Published in: Leukemia & lymphoma (2019)
Keyphrases
  • acute lymphoblastic leukemia
  • allogeneic hematopoietic stem cell transplantation
  • electronic health record
  • deep learning